Literature DB >> 18985704

A flexible strategy for testing subgroups and overall population.

Mohamed Alosh1, Mohammad F Huque.   

Abstract

Subgroup analyses in addition to the total study population analysis are common in clinical trials. However, it is well recognized that findings from subgroup analyses do not provide confirmatory evidence for subgroup treatment effects without placing a priori criteria for ensuring that their findings are scientifically sound. In this paper we address some of the common pitfalls of subgroup analyses. Subgroups analyses inherently have low power for detecting treatment effects. We investigate the power interplay for a subgroup analysis and that for the total study population and list factors that impact the power of a subgroup analysis. Then we introduce a flexible statistical strategy for testing a pre-specified sequence of hypotheses for both the overall and a subgroup. The proposed method strongly controls the familywise Type I error rate and enjoys higher power than other traditional methods. This testing strategy allows testing for a subgroup once a pre-specified degree of consistency in the efficacy findings between the subgroup and the overall study population is met. In addition, it accounts for the dependency between test statistics for the subgroup and the overall study population. We discuss the power performance of this new method and provide significance levels for subgroup analysis. Finally, we illustrate its application through retrospective analysis of data from three published clinical trials. Copyright (c) 2008 John Wiley & Sons, Ltd.

Mesh:

Year:  2009        PMID: 18985704     DOI: 10.1002/sim.3461

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  13 in total

1.  Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests.

Authors:  Frank Bretz; Martin Posch; Ekkehard Glimm; Florian Klinglmueller; Willi Maurer; Kornelius Rohmeyer
Journal:  Biom J       Date:  2011-08-12       Impact factor: 2.207

2.  Uniformly Most Powerful Tests for Simultaneously Detecting a Treatment Effect in the Overall Population and at Least One Subpopulation.

Authors:  Michael Rosenblum
Journal:  J Stat Plan Inference       Date:  2014-07-10       Impact factor: 1.111

Review 3.  Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Ruwanthi Kolamunnage-Dona; Andrea L Jorgensen
Journal:  J Pers Med       Date:  2017-01-25

4.  Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.

Authors:  Jungnam Joo; Nancy L Geller; Benjamin French; Stephen E Kimmel; Yves Rosenberg; Jonas H Ellenberg
Journal:  Clin Trials       Date:  2010-08-06       Impact factor: 2.486

5.  Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker.

Authors:  Neha Joshi; Jason Fine; Rong Chu; Anastasia Ivanova
Journal:  J Biopharm Stat       Date:  2019-07-04       Impact factor: 1.051

6.  Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.

Authors:  Benjamin French; Jungnam Joo; Nancy L Geller; Stephen E Kimmel; Yves Rosenberg; Jeffrey L Anderson; Brian F Gage; Julie A Johnson; Jonas H Ellenberg
Journal:  Trials       Date:  2010-11-17       Impact factor: 2.279

7.  Adaptive designs for subpopulation analysis optimizing utility functions.

Authors:  Alexandra C Graf; Martin Posch; Franz Koenig
Journal:  Biom J       Date:  2014-11-14       Impact factor: 2.207

Review 8.  Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes.

Authors:  Julien Tanniou; Ingeborg van der Tweel; Steven Teerenstra; Kit C B Roes
Journal:  BMC Med Res Methodol       Date:  2016-02-18       Impact factor: 4.615

Review 9.  Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.

Authors:  Thomas Ondra; Alex Dmitrienko; Tim Friede; Alexandra Graf; Frank Miller; Nigel Stallard; Martin Posch
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

10.  Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs.

Authors:  Nicolás M Ballarini; Thomas Burnett; Thomas Jaki; Christoper Jennison; Franz König; Martin Posch
Journal:  Stat Med       Date:  2021-03-29       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.